Plus Therapeutics Shares Surge on Analyst Upgrade and Insider Buying

Shares of Plus Therapeutics experienced significant upward momentum in today’s trading session, propelled by a combination of revised analyst projections and substantial insider acquisitions. The stock advanced as much as 14.79% since market open, demonstrating unusually strong market activity.

Market Experts Boost Confidence

The rally received substantial support from Ascendiant Capital, where analyst Edward Woo maintained his “Buy” recommendation while increasing the price target from $20.50 to $21.00—representing a 2.44% upward adjustment. This vote of confidence wasn’t isolated within the financial community:

• D. Boral Capital continues to endorse the equity with a “Buy” rating and maintains a $5.00 price objective
• Maxim Group sustains its “Buy” stance despite reducing its target from $4.00 to $3.00
• The collective assessment from four brokerage firms indicates an “Outperform” rating of 2.0

Corporate Leadership Demonstrates Conviction

The confidence in Plus Therapeutics extends beyond external analysis, with Director Robert P. Lenk substantially increasing his position through the purchase of 110,000 shares at an average price of $0.49 per unit. This transaction, valued at $53,900, expanded his holdings by an impressive 375.08%, signaling strong internal belief in the company’s prospects.

Should investors sell immediately? Or is it worth buying Plus Therapeutics?

Trading metrics underscore the heightened investor interest, with volume reaching 49.91 million shares and market capitalization standing at $82.89 million.

Operational Milestones Underpin Momentum

Fundamental developments provide substance behind the price movement. The company secured a national agreement with UnitedHealthcare, effective September 15, 2025, extending insurance coverage to more than 51 million individuals. Additionally, the CNSide® CSF Assay Platform demonstrates robust performance metrics with 92% sensitivity and 95% specificity, strengthening the diagnostic business foundation.

The convergence of optimistic analyst revisions, substantial insider accumulation, and concrete operational achievements has generated notable forward momentum for Plus Therapeutics shares. Market activity confirms that decisive signals from both internal and external stakeholders can significantly influence market dynamics.